Introduction

In the news: Dr. Dimov is the current president of the Florida Allergy, Asthma & Immunology Society (FAAIS). He was named one of The top 50 science stars of Twitter by the journal Science. Dr Dimov was interviewed by the Chicago Tribune: Illness threatens the best of barbecuers. He authored an article on 'Googling' anaphylaxis in the journal of Curr Opin Allergy Clin Immunol. in 2019.

Dr. Dimov is an Allergist/Immunologist at Cleveland Clinic Florida and Clinical Associate Professor, FAU Charles E. Schmidt College of Medicine. He is the President of the Florida Allergy, Asthma & Immunology Society (FAAIS). Dr. Dimov has served in several leadership positions at the World Allergy Organization (WAO) and the American Academy of Allergy Asthma and Immunology (AAAAI). Dr. Dimov has published more than 140 scientific papers, book chapters and abstracts, including the WAO Anaphylaxis Guidelines. He is the founder of internationally acclaimed websites, such as AllergyGoAway.com and PeriopMedicine.org, which had received more than 10 million page views, and were hyperlinked in the websites of 37 medical schools.

Click here for a current CV and a list of research projects and publications. To learn more, please read the Medscape.com interviews with Dr. Dimov: Popular Case-Based Resource Models Online Medical Training and Clinical Cases Make Blog a Popular Resource.

Dr. Dimov has clinics 5 days a week at Cleveland Clinic Florida, from Monday to Friday. Click here to request an appointment at Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd.
Weston, FL 33331

NEJM Advisory Board for Students and Residents

In 2008, Dr. Dimov was appointed a Member of the New England Journal of Medicine (NEJM) Advisory Board for Students and Residents, and served in this position for two years. Founded in 1812, the NEJM is considered the most authoritative medical journal in the world and it carries the highest impact factor (51) among biomedical journals.

Photo on the right: Dr. Jeffrey Drazen, Editor-in-Chief of the NEJM and Dr. Ves Dimov during the NEJM Horizons Conference which focused on pushing the boundaries of traditional medical publishing, Babson Executive Conference Center, Boston, Massachusetts, October 24-26, 2008.

Dr. Dimov summarized his impressions from the conference and recommendations in the three-part series NEJM Horizons Conference to Push Boundaries of Traditional Medical Publishing - Day 1, Day 2, and Day 3.

Web Site Disclaimer

Click here for the full text.

All opinions expressed here are those of their authors and not of their employer.

Information provided here is for medical education only. It is not intended as and does not substitute for medical advice. If you are a patient, please see your doctor for evaluation of your individual case. Under no circumstances will the authors be liable to you for any direct or indirect damages arising in connection with use of this website.

The appearance of external hyperlinks to other websites does not constitute endorsement. We do not verify, endorse, or take responsibility for the accuracy, currency, completeness or quality of the content contained in these sites.

There are no real life patient data on this website. Please note: we do not write or “blog” about patients. All case descriptions are fictional, similar to the descriptions you can find in a multiple choice questions textbook for board exam preparation. Cases course and description do not follow real cases.

Please report a suspected HIPAA violation to clinicalcases@gmail.com.

Updated: 08/27/2014

Email Usage and Terms of Agreement

We striclty comply with the the HIPAA law in the U.S. (summarized below):

HIPAA Confidentiality Provisions

The HIPAA Security Standard contains two subparts that relate directly to data integrity, data access, and mechanisms for handling data. The part most relevant to email is the rule requiring "securing patient records containing individually identifiable health information so that they are not readily available to those who do not need them." The relevant HIPAA subparts include:

45 CFR Part 142, § 142.308 (c). “Technical security services to guard data integrity, confidentiality and availability.” These are processes that protect information and control individual access to information.

45 CFR Part 142, § 142.308 (d). “Technical security mechanisms.” These are controls that prevent unauthorized access to information that is transmitted across an internal network or across the public Internet.

By definition, regular email is apparently not confidential unless encrypted, something your email to us will not be. Thus, our receipt of your email tells us that you are willing to waive any confidentiality provisions of the HIPAA. Our physician responses to you should not be considered confidential either. While we have no intention of telling anyone about your email, you may wish to pursue any private matters confidentially by mail, fax, or personal visit. We will not discuss medical matters over the phone if you have never been seen in our office.

If you do not wish to email us due to privacy concerns, please make an appointment or mail / fax us a letter with your concerns.

Regular email should NOT include any info that you would not want a thief to see (if the email gets intercepted).

By submitting your email to use to confirm the following: "I have read, understood, and waive any HIPAA confidentiality provisions related to regular email communication. By proceeding, you hereby agree to hold our physicians and affiliates harmless from any hacking or any other unauthorized use of your personal information by outside parties."

Published: 09/30/2011
Updated: 09/30/2011

Research Experience of Ves Dimov, M.D.

Dr. Dimov has published more than 140 scientific papers, book chapters, interviews, and abstracts. He has been an investigator on 60 research projects and clinical trials. See Google Scholar citations and PubMed.

A list of ongoing and future research projects is available here and a spreadsheet is embedded below:



RESEARCH EXPERIENCE

2012-2014
Principal investigator. Incidence of insufficient response to pneumococcal immunizations and selective antibody deficiency with normal immunoglobulins  (SADNI) among patients with chronic sinusitis and recurrent otitis media

2011-2013
Principal investigator. Investigating the etiology of chronic urticaria and the role of H. pylori, vitamin D, anti-IgE receptor antibodies.

2011-2013
Principal investigator. Characteristics of the Professional Use of the Social Network Twitter by Allergists and Immunologists. University of Chicago. N. Fenny, V. Dimov, R. Wolf.

2010-2012
Investigator. Childhood Rhinitis, Skin Testing, and Effects of Breast Milk Exposure. University of Chicago. R. Wolf, V. Dimov.

2010-2012
Investigator. AsthmaNet, multi-centered network examining novel therapeutic approaches to asthma in children and adults, funded by the National Heart, Lung and Blood Institute (NHLBI).

2010-2011
Principal investigator. Patient reception of iPad as a clinical education tool. University of Chicago. V. Dimov, A. Nickels, R. Wolf.

2008-2010
Investigator. The Effects of the PPAR-gamma Agonist Rosiglitazone on Airway Hyperreactivity. Creighton University Division of Allergy & Immunology, Omaha, Nebraska. Wichman T, Casale T. Available at: http://clinicaltrials.gov/ct2/show/NCT00614874.

2008-2009
Principal Investigator. Online Case-based curriculum of Allergy and Immunology for education of fellows in training. Creighton University Division of Allergy & Immunology, Omaha, Nebraska, Louisiana State University Health Sciences Center (Shreveport).

2007-2008
Investigator. Podcast as a Medical Education Tool in an Internal Medicine Residency Program. Auron M, Dimov V, Nielsen C. Cleveland Clinic, Cleveland, Ohio.

2006-2008
Principal Investigator. Risk factors for Acute Renal Failure after Noncardiac Surgery (RANCS). A retrospective review of 21,000 patients at the Cleveland Clinic. Dimov V, Usmani A, Jaffer A, Schreiber M, Kumar A, Lascano M, Rajamanickam A, V. Molina, Hixson E. Cleveland Clinic, Cleveland, Ohio.

2006-2008
Principal Investigator. Awareness of Renal Function Status and Chronic Kidney Disease in Patients with Diabetes (ARF CD). Dimov V, Kumar A. Cleveland Clinic, Cleveland, Ohio.

2006-2007
Principal Investigator. How to Stay Up-to-date with the Literature: A Web Feeds Portal for Scientific Journals. Dimov V, Kumar A. Cleveland Clinic, Cleveland, Ohio.

2005-2007
Investigator. Perioperative beta-blocker dose titration and clinical outcomes during major noncardiac surgery. Aneja A, Harte B, C. Phillips, Dimov V, Usmani A, Michota F, Jaffer A, Kumar A. Cleveland Clinic, Cleveland, Ohio.

2005-2006
Investigator. INCREASE, Optimization of beta-blocker use in the perioperative period of noncardiac surgery. Aneja A, Harte B, Hixson E, Jaffer A, Singh V, Dimov V. Cleveland Clinic, Cleveland, Ohio.

2005-2006
Investigator. Improvement of Perioperative Beta-blocker Use through Electronic Medical Record-based Best Practice Alert (PBB & BPA Study). Aneja A, Harte B, Hixson E, Jaffer A, Singh V, Dimov V. Cleveland Clinic, Cleveland, Ohio.

2004-2006
Principal Investigator. A Web Log Software Platform as a Medium for Medical Education. Dimov V, Kumar A, Uzunova-Dimova K. Case Western Reserve University (St. Vincent/St. Luke) and Cleveland Clinic, Cleveland, Ohio.

2004
Principal Investigator. Assessment of Effectiveness of a Blog Website Created and Maintained by the Medical Residents for Improving Postgraduate Medical Education. Dimov V, Case Western Reserve University (St.Vincent/St.Luke) Internal Medicine Residency Program, Cleveland, Ohio

2003
Investigator. West Nile Virus Infection - the Experience of Hospitals in Cuyahoga County, Ohio. A. Brobbey, Case Western Reserve University, Cleveland, Ohio.

2001
Investigator. Tidal Breathing Analysis in Evaluating Bronchial Obstruction in Children. Filtchev S, Medical University Sofia.

1999-2000
Investigator. Intercontinental Childhood ITP Study Group. Registry of Children with Idiopathic Thrombocytopenic Purpura. Tom Kuhne, Basel University, Switzerland. Prof. Kalev I, Medical University Sofia. Results published in the Lancet, Vol.358, Dec 22/29, 2001.

2000
Investigator. Cytological Comparison of Nasal Smear and Bronchoalveolar Lavage Fluid in Children with Rhinosinusitis and Asthma. Ulevinov N, Medical University Sofia.

2000
Investigator. Pulmonary Complications after Influenza Virus Infection. Prof. Kalev I, Medical University Sofia.

1998
Investigator. Molecular Diagnosis of Hemophilia A in Bulgaria by DNA Analysis Using Polymorphisms Within And Outside Factor VIII Gene. Prof. I.Kremenski, Medical University Sofia.

1996
Investigator. Jarisch-Herxheimer Reaction during Treatment of Patients with Syphilis. Prof. K. Pramatarov, Dermatology and Sexual Transmitted Diseases Hospital, Medical University Sofia.

CLINICAL RESEARCH TRIALS EXPERIENCE

2011-2013
A 6-Month Safety and Benefit Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in The Treatment of 6,200 Pediatric Subjects 4-11 Years Old with Persistent Asthma SAS115358, VESTRI Trial, GlaxoSmithKline (GSK) Research & Development.

2009-2010
Investigator. Pfizer B0871006. A Study to Investigate The Efficacy and Safety of Inhaled PF-00241939 Using CRC-749 Dry Powder Inhaler. Casale T, Creighton University Division of Allergy & Immunology.

2009-2010
Investigator. Schering-Plough P05234. A M Multi-Center, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed (Ambrosia artemisiifolia) Sublingual Tablet (SCH39641) in Adult Subjects With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma. Casale T, Creighton University Division of Allergy & Immunology.

2009-2010
Investigator. A Phase II, Randomized, Double-Blind, Placebo-Controlled study to Evaluate the Safety, Tolerability and Efficacy of Lebrikizumab (MILR 444A) in Adult Patients with Asthma who are Inadequately Controlled on Inhaled Corticosteroids. Casale T, Creighton University Division of Allergy & Immunology.

2009-2010
Investigator. Capnia Protocol C218. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Pilot Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide Used Four Times a Day in the Symptomatic Treatment of Seasonal Allergic Rhinitis. Casale T, Creighton University Division of Allergy & Immunology.

2009-2010
Investigator. CQMF149A2210. A randomized, multi-center, parallel group, double blind, study to assess the safety of QMF Twisthaler (500/400μg) and mometasone furoate Twisthaler (400μg) in adolescent and adult patients with persistent asthma. Casale T, Creighton University Division of Allergy & Immunology.

2009-2010
Investigator. Novartis Protocol CNVA237. A 52-Week Treatment, Randomized, Double-Blind, Placebo-Controlled, With Open Label Tiotropium, Parallel-Group Study To Assess The Efficacy, Safety And Tolerability Of NVA237 In Patients With Chronic Obstructive Pulmonary Disease. Casale T, Creighton University Division of Allergy & Immunology.

2009-2010
Investigator. Pfizer PF-0419183. A Phase 2A, Randomized, Double-Blind (3rd Party Open), Double-Dummy, Placebo and Active Controlled 5-way Crossover Study to Assess the Bronchodilatory Action, Safety, Toleration and Pharmacokinetics of Single Oral Doses of PF-04191834 in Asthmatic Patients. Casale T, Creighton University Division of Allergy & Immunology.

2008-2010
Investigator. Boehringer Ingelheim 1012.57. A Multi-Center, Randomized Study Starting with a 4-week, 2-way crossover double-blind Treatment Phase Comparing the Efficacy and Safety of Combivent CFC MDI to Albuterol HFA MDI followed by a 4-week Open-Label Combivent Respimat Treatment Phase when All Study Drugs are Used for Symptom Relief “as needed” in Patients With Moderate-to Severe Asthma (GINA 2207 Treatment Steps 3 to 5). Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. GSK FFR110537. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110 mcg in Adults and Adolescents 12 years of Age and Older with Perennial Allergic Rhinitis. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. Stallergenes V061.08. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Study of the Efficacy and Safety Of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-Based Tablets Once Daily to Adult Patients Suffering From Grass Pollen Rhinoconjunctivitis. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. MedImmune MI-CP143. Phase IIa Randomized Double-Blind Placebo-Controlled Dose-Escalating Study to Evaluate the Safety and Effect on Exercise Challenge Testing of Multiple Fixed Subcutaneous Doses of MEDI-528, a Humanized Anti-Interleukin-9 Monoclonal Antibody in Adults With Stable Asthma and Exercise-Induced Bronchoconstriction. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. Merck. The Effect of Montelukast In-Vitro on Basophil, Histamine and Leukotriene, IL-4 and IL-13 Release in Subjects with Allergic Rhinitis or Allergic Asthma. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. Capnia C215. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide in the Treatment of Seasonal Allergic Rhinitis. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. Merck 388-00. A Phase Ib Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Bronchodilatory Effect of MKL-0476 in Patients with Chronic Asthma. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. Greer Labs. (SLIT 07-01). Parallel, Randomized Double-Blind, Placebo-Controlled Trial in Adults for the Sublingual-Oral Immunotherapy (SLIT) of Allergic Rhinoconjunctivitis With or Without Asthma Caused by Ragweed Pollen. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. Capnia C213. A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Evaluate the Effect of Nasal Carbon Dioxide on Nasal Congestion via Acoustic Rhinometry in Subjects with Perennial Allergic Rhinitis. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. Exhaled Breath Condensate and Nitric Oxide: Non-invasive Evaluation of lung Disease After Treatment with Xolair. Novartis Pharmaceuticals. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils. Novartis Pharmaceuticals. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. A randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Phase II Study to Determine the Safety and Efficacy of AMG317 I Subjects with Moderate to Severe Asthma. Amgen, Incorporated. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. A randomized, Double-Blinded, Placebo Controlled, Parallel group, Multi-center Study to assess Safety Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous doses of QAX576 in Moderate Persistent Allergic Asthmatics following Inhaled Corticosteroid Withdrawal. Novartis Pharmaceuticals. Casale T, Creighton University Division of Allergy & Immunology.

2007-2008
Investigator. Human Pasteurized C1 Esterase Inhibitor Concentrate (CE1145) in Subjects With Congenital C1-INH Deficiency And Acute Abdominal or Facial HAE Attacks. ZLB Behring. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. C-05-69 Safety Study of Olopatadine Nasal Spray. Alcon Research, Ltd. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. A Randomized, Placebo-Controlled Double-Blind Study to Test the efficacy and Safety/Tolerability of Grass MATAMPL. Allergy Therapeutics. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Study the Efficacy and Safety of Oral Microencapsulated Ragweed Pollen extract Administered Prior and During Ragweed Pollen Season. Curaologic. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. A 26-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Adaptive, Seamless, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of 2 Doses of Indacaterol (selected from 75, 150, 300 and 600 ug/od) in Patients with Chronic Obstructive Pulmonary Disease Using Blinded Formoterol (12 ug BID) and Open Label Tiotropium (18 ug od) as Active Controls.Novartis Pharmaceuticals. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. A Randomized, Placebo-Controlled Double-Blind Study to Test the Efficacy and Safety/Tolerability of Ragweed MATAMPL. Allied Therapeutics. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. The Effect of Roflumilast In-Vitro on Basophil, Histamine and Leukotriene, IL-4 and IL-13. Altana, Incorporated. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. A Phase IIa, Multi-Center, Randomized, Double-Blind Placebo-Controlled, Parallel, Dose-finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab on Subjects with Refractory Asthma. Abbott Labs. Casale T, Creighton University Division of Allergy & Immunology. Casale T, Creighton University Division of Allergy & Immunology.

2008
Investigator. A 26-week Treatment, Randomized Multicenter, Double-Blind, Double-Dummy, Parallel-Group Study to Assess the Safety of Indacaterol (300 and 600 ug od) in Patients with Moderate to Severe Persistent Asthma, Using Salmeterol (50 ug bid) as an Active Control. Novartis Pharmaceuticals. Casale T, Creighton University Division of Allergy & Immunology.

2002-2003
Investigator. SD-039-0682 (SAMBA). A 12-week, randomized, double-blind, parallel-group, multicentre, phase-III study to compare the efficacy and safety of Symbicort pMDI (budesonide/formoterol 80/4.5 µg 2 actuations b.i.d., delivered dose) with that of Pulmicort pMDI (budesonide 100 µg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler (budesonide/formoterol 80/4.5 µg 2 inhalations b.i.d., delivered dose) in children with asthma. AstraZeneca R & D, Lund, Sweden. Prof. Kalev I, Medical University Sofia.

2001-2002
Investigator. SD-039-0673 (STAY). Efficacy and Safety of Budesonide/Formoterol (Symbicort)) Turbuhaler as Single Therapy in Patients Aged 6-80 years with Mild-Moderate Asthma. Comparison with Symbicort Turbuhaler and Pulmicort Turbuhaler as Maintenance Therapy, Both Complemented with Bricanyl Turbuhaler. International, Multicentre, Double blind, Randomized, Active-controlled Study. L. Laxmyr, AstraZeneca Research & Development, S-221 87 Lund, Sweden. Prof. Kalev I, Medical University Sofia.

2001
Investigator. HMR 3647B/2001. Multicentre, Phase II, Open Label Study of the Efficacy, Safety, Acceptability, and Pharmacokinetics of Telithromycin, after repeated Oral Administration of Either of Two Doses, Once Daily, for 5 days or 7 days, in the Treatment of Respiratory Tract Infections in Children of 6 months to 12 years. Dr Emmanuelle Butticaz-Iroudayssamy, Aventis Pharma, Hoechst Marion Roussel R & D, Romainville, France. D. Youngblood, Quintiles, Inc., Kansas City, MO, USA. Prof. Kalev I, Medical University Sofia.

2000-2001
Investigator. SAM 40012 International, Multicentre, Randomized, Parallel Group Comparison of Three Treatments: 1. Salmeterol and Fluticasone, 2. Fluticasone 200 mcg bd, 3. Fluticasone 100 mcg bd in Children aged 4-11 years with Asthma. L. Norcross, GlaxoSmithKline Research and Development, Uxbridge, UK. Prof. Kalev I, Medical University Sofia.

2000-2001
Investigatort. Budesonide Efficacy and Safety in Children aged 5-15 years with Asthma over a 26-week Treatment Period. For Astra Zeneca Research. Prof. Kalev I, Medical University Sofia.

1999-2000
Investigator. FAS 30009 International, Multicentre, Randomized Study to Assess the Long Term Safety of Fluticasone Propionate Compared with Sodium Cromoglycate in Children aged 12-47 Months with Asthma over a 52-week Treatment Period. P. Davis, GlaxoSmithKline R & D, Uxbridge, UK. Prof. Kalev I, Medical University Sofia. Results presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 58th Annual Meeting - March 1-6, 2002, New York; published in the Journal of Allergy and Clinical Immunology, part 2, Vol.109, No 1, Jan 2002.

1999
Investigator. Clarithromycin Use, Safety and Efficacy in Children aged 1-12 years with Infections of Upper and Lower Respiratory Tract. For Abbot Laboratories. Prof. I.Kalev, Medical University Sofia.

1999
Investigator. Midecamycin Effect in Children aged 2 to 12 years with Otitis Media, Bronchitis and Pneumonia. Prof. Kalev I, Medical University Sofia.

PUBLICATIONS

Click here to see the complete list.

Published: 06/21/2008
Updated: 08/17/2014

Medical Web Logs

A medical web log is a website with regular entries of commentary on medical news and descriptions of events related to medicine. Entries are displayed in reverse chronological order. Dr. Dimov currently maintains 2 of the most popular medical web logs:

CasesBlog - Medical and Health Blog

The web log of ClinicalCases.org was started at Case Western Reserve University and Cleveland Clinic and is focused on medical news and social media. It is ranked in the top 50 of Healthcare 100 Top Blogs and has more than 17,000 daily subscribers via RSS. Clinical Cases and Images - Blog is featured by the Nature Publishing Group portal for high-quality science blogs (Nature Blogs).

British Medical Journal
Editorials, How Web 2.0 is changing medicine, Dean Giustini
BMJ 2006;333:1283-1284 (23 December)

"One of the best blogs in medicine is Ves Dimov's Clinical Cases and Images - Blog. It contains a rich collection of "presurfed" material for busy clinicians and features interactivity and timely discussion. Dimov is also a supporter of medical librarian bloggers. Why waste time fumbling with search engines when you can consult this blog for timely updates? As well as case discussions, Ves provides links to today's medical headlines from Reuters and clinical images via a dynamic, free photo sharing tool called Flickr. One of his slide presentations "Web 2.0 in medicine" is available on Slideshare (itself a fantastic new 2.0 tool). Clinical Cases and Images is a virtual laboratory for doctors and medical librarians interested in Web 2.0."

The website has been a finalist in the Annual Medical Weblog Awards multiple times in the categories for Best Medical Weblog, Best Clinical Sciences Weblog and Best Medical Technologies/Informatics Weblog.

Dr. Dimov was credited with first using the term "Web 2.0 in Medicine" in articles and presentations in October 2005. Click here to see his 2009 update of the presentation Web 2.0/Social Media in Medicine.

Allergy Notes

The web log was at started at Case Western Reserve University and Cleveland Clinic, and publishes allergy, asthma & immunology news updated daily. Allergy Notes is the official blog of Allergy Cases.org, the most popular case-based curriculum of allergy and immunology.

Allergy Notes is included in the Nature Publishing Group portal for high-quality science blogs (Nature Blogs).

Twiter followers: @Allergy and @DrVes

Dr. Dimov maintains one of the most popular physician accounts on Twitter @DrVes. It has more than 8,000 followers and a Grader score of 100 (of maximum 100), ranking it among the top of more than 8 million accounts. The allergy-specific account is @Allergy.

As an experienced website editor and EMR expert, Dr. Dimov can help your practice with website development, social media tools (RSS, Twitter, blog, podcast, video), and EMR/EHR. Visitor statistics for ClinicalCases.org alone include more than 7 million page views, 3 million visitors, 17,000 daily subscribers via RSS and email, 8,000 Twitter followers, 2,000 Facebook fans.

HONORS/AWARDS


2009, 2010
Finalist, Best Medical Weblog for Clinical Cases and Images, Annual Medical Weblog Awards of Medgadget.com.

2006, 2007, 2008, 2009, 2010
Finalist, Best Clinical Sciences Weblog for Clinical Cases and Images, Annual Medical Weblog Awards of Medgadget.com.

2010
Finalist, Best Clinical Sciences Weblog for Allergy Notes, Annual Medical Weblog Awards of Medgadget.com.

2006, 2007, 2008
Finalist, Best Medical Technologies/Informatics Weblog for Clinical Cases and Images, Annual Medical Weblog Awards of Medgadget.com.

Published: 06/11/2008
Updated: 01/28/2012